Šalis: Jungtinės Valstijos
kalba: anglų
Šaltinis: NLM (National Library of Medicine)
RISPERIDONE (UNII: L6UH7ZF8HC) (RISPERIDONE - UNII:L6UH7ZF8HC)
Aurolife Pharma LLC
RISPERIDONE
RISPERIDONE 0.25 mg
ORAL
PRESCRIPTION DRUG
Risperidone tablets, USP are indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods [see Clinical Studies (14.4)] . Pregnancy Category C. The teratogenic potential of risperidone was studied in three Segment II studies in Sprague-Dawley and Wistar rats (0.63 to 10 mg/kg or 0.4 to 6 times the maximum recommended human dose [MRHD] on a mg/m2 basis) and in one Segment II study in New Zealand rabbits (0.31 to 5 mg/kg or 0.4 to 6 times the MRHD on a mg/m2 basis). The incidence of malformations was not increased compared to control in offspring of rats or rabbits given 0.4 to 6 times the MRHD on a mg/m2 basis. In three reproductive studies in rats (two Segment III and a multigenerational study), there was an increase in pup deaths during the first 4 days of lactation at doses of 0.16 to 5 mg/kg or 0.1 to 3 times the MRHD
Abbreviated New Drug Application
RISPERIDONE - RISPERIDONE TABLET, FILM COATED AUROLIFE PHARMA LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RISPERIDONE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RISPERIDONE TABLETS, USP. RISPERIDONE TABLETS, USP INITIAL U.S. APPROVAL: 1993 WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. RISPERIDONE IS NOT APPROVED FOR USE IN PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. (5.1) RECENT MAJOR CHANGES Warnings and Precautions, Metabolic Changes(5.5) September 2011 INDICATIONS AND USAGE Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults and adolescents aged 13 to 17 years (1.1) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults, and alone in children and adolescents aged 10 to 17 years (1.2) Treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years_ (_1.3_)_ DOSAGE AND ADMINISTRATION Initial Dose T itration T arge t Dose Effe ctive Dose Range Schizophre nia - adults (2.1) 2 mg/day 1 to 2 mg daily 4 to 8 mg daily 4 to 16 mg/day Schizophre nia - adolescents (2.1) 0.5 mg/day 0.5 to 1 mg daily 3 mg/day 1 to 6 mg/day Bipolar mania – adults (2.2) 2 to 3 mg/day 1 mg daily 1 to 6 mg /day 1 to 6 mg/day Bipolar mania in children/adolescents (2.2) 0.5 mg/day 0.5 to 1 mg daily 2.5 mg/ day 0.5 to 6 mg/day Irritability associated with autistic disorder (2.3) 0.25 mg/day (<20 kg) 0.5 mg/day (≥20 kg) 0.25 to 0.5 mg at ≥ 2 weeks 0.5 mg/day (<20 kg) 1 mg /day (≥20 kg) 0.5 to 3 mg/day DOSAGE FORMS AND STRENGTHS Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg (3) CONTRAINDICATIONS Known hypersensitivity to the product (4) WARNIN Perskaitykite visą dokumentą